Axsome Therapeutics Inc.
Axsome Therapeutics Reports Strong Q2 2024 Financial Results and Pipeline Updates
Summary
Axsome Therapeutics, Inc. announced its financial results for Q2 2024, reporting total net product revenue of $87.2 million, reflecting an 87% year-over-year growth. Auvelity net product sales increased by 135% to $65.0 million, and Sunosi net product revenue grew by 16% to $22.1 million. The company also provided updates on its development pipeline, including the resubmission of the NDA for AXS-07 in migraine, and anticipated topline results for several Phase 3 trials in the second half of 2024. Additionally, Axsome resolved patent litigation with Unichem Laboratories Ltd. regarding Sunosi, with Unichem permitted to market its generic version starting June 30, 2042.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement